| 2024/29/11 - 20:00 |
|
ABIONYX Pharma announces the approval of all resolutions put to the vote at its Combined General Meeting on November 28, 2024
|
pdf
|
| 2024/14/11 - 19:00 |
|
ABIONYX Pharma provides an update on its business and cash position for the third quarter of 2024
|
pdf
|
| 2024/07/11 - 07:00 |
|
ABIONYX Pharma announces the main resolutions proposed at the next Combined General Meeting on November 28, 2024, and the availability of related documents
|
pdf
|
| 2024/24/10 - 19:30 |
|
ABIONYX Pharma RACERS study clinical results in brain-fog selected for Poster Presentation at the American Society of Nephrology (ASN) 2024 Annual Meeting "Kidney Week"
|
pdf
|
| 2024/21/10 - 20:00 |
|
ABIONYX Pharma received positive feedback from the EMA for CER-001 in LCAT Deficiency
|
pdf
|
| 2024/26/09 - 18:30 |
|
ABIONYX Pharma announces its 2024 Half-Year financial results
|
pdf
|
| 2024/22/08 - 18:00 |
|
ABIONYX Pharma provides an update on its business and cash position for the 1st half of 2024
|
pdf
|
| 2024/01/07 - 08:00 |
|
ABIONYX carries out successfully a capital increase with cancellation of preferential subscription rights for the benefit of a category of persons through the issue of shares with warrants for an amount of c.€3.4 million
|
pdf
|
| 2024/27/06 - 19:00 |
|
ABIONYX Pharma announces unanimous approval of all resolutions put to the vote at its Combined General Meeting
|
pdf
|
| 2024/19/06 - 19:30 |
|
ABIONYX decides on a capital increase with cancellation of preferential subscription rights for the benefit of a category of persons through the issue of shares with warrants for an amount of c.€3.4 million
|
pdf
|
| 2024/13/06 - 19:30 |
|
ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis
|
pdf
|
| 2024/16/05 - 18:00 |
|
ABIONYX Pharma provides an update on its activity and cash position for the 1st quarter 2024
|
pdf
|
| 2024/02/05 - 18:00 |
|
Availability of the Universal Registration Document for the year 2023
|
pdf
|
| 2024/14/03 - 18:00 |
|
Bpifrance supports the development of CER-001 in ophthalmology with a nearly €1 million non-dilutive innovation grant
|
pdf
|
| 2024/11/03 - 07:30 |
|
ABIONYX Pharma announces its 2023 full-year financial results
|
pdf
|
| 2024/07/03 - 19:00 |
|
ABIONYX Pharma announces its financial calendar for the year 2024
|
pdf
|
| 2024/29/02 - 18:08 |
|
ABIONYX Pharma provides an update on its activity and cash position for the 4th quarter 2023
|
pdf
|
| 2024/16/02 - 08:00 |
|
Clarification about clinical results from the phase 3 of apoA-I study, CSL112
|
pdf
|
| 2024/15/02 - 18:00 |
|
Clinical results of the Phase 3 AEGIS-II study: - Validation of ABIONYX Pharma's strategic repositioning in severe diseases with short apoA-I treatment - No safety or tolerability problems in 18,000 patients
|
pdf
|
| 2024/08/01 - 18:03 |
|
ABIONYX Pharma appoints Rob Scott, MD, as Chief Medical Officer and Head of R&D
|
pdf
|
